Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

Clinical Microbiology and Infection(2022)10.1016/j.cmi.2022.04.004Source: DataRank Database

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations is a research paper published in Clinical Microbiology and Infection (2022). On theSindex it has a DataRank of 0. It has been cited 48 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access48 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (16)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Nassim Anjidani ORCID,Ramin Shahpari,Masoud Mardani ORCID,Araz Sabzvari,Babak Yazdani

Live enrichment

PubMed:35436611 PMC:PMC9012510

National Institutes of Health

Grant: HHSN272201800044C

NIAID NIH HHS

Grant: HHSN272201800024C

CinnaGen

National Institute of Allergy and Infectious Diseases

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9012510

publisherhttps://api.elsevier.com/content/article/PII:S1198743X22002075?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1198743X22002075?httpAccept=text/plain

Europe_PMChttps://europepmc.org/articles/PMC9012510

Europe_PMChttps://europepmc.org/articles/PMC9012510?pdf=render

MeSH Terms

HumansInulinVaccines, SubunitAntibodies, ViralDouble-Blind MethodAntibodies, NeutralizingSpike Glycoprotein, CoronavirusCOVID-19SARS-CoV-2COVID-19 Vaccines

Keywords

Phase 2Subunit Protein VaccineCovid-19Sars-cov-2Advax-cpgSpikogen